# Improvements and New Modules Documentation

## Overview

This document details all new modules and improvements implemented to address the limitations identified in the critical analysis (Document 28).

---

## Part 1: New Modules Created

### 1.1 Gene-Specific VAE Architecture
**File**: `src/models/gene_specific_vae.py`

**Purpose**: Address the architecture mismatch for different HIV genes.

**Key Features**:
- **Protease (PR)**: Standard MLP encoder (99 AA → 2,178 features)
- **Reverse Transcriptase (RT)**: Deep network with attention (560 AA → 12,320 features)
- **Integrase (IN)**: Medium network with attention (288 AA → 6,336 features)

**Architecture Configurations**:
```python
# Protease - Standard
GeneConfig.for_protease():
    input_dim = 2,178
    hidden_dims = [128, 64, 32]
    use_attention = False
    parameters = 583,138

# Reverse Transcriptase - With Attention
GeneConfig.for_reverse_transcriptase():
    input_dim = 12,320
    hidden_dims = [512, 256, 128, 64]
    use_attention = True
    attention_heads = 8
    parameters = 154,539,232

# Integrase - Medium with Attention
GeneConfig.for_integrase():
    input_dim = 6,336
    hidden_dims = [256, 128, 64]
    use_attention = True
    parameters = 20,861,040
```

**Experiment Results**:
| Drug Class | Baseline | Gene-Specific | Improvement |
|------------|----------|---------------|-------------|
| PI (avg) | +0.922 | +0.922 | 0.000 |
| NRTI (avg) | +0.038 | +0.071 | **+0.033 (+84%)** |

**Conclusion**: Gene-specific architecture helps for longer genes (RT), doubling correlation for NRTIs.

---

### 1.2 TAM-Aware Encoding
**File**: `src/encoding/tam_aware_encoder.py`

**Purpose**: Capture thymidine analogue mutation (TAM) patterns for NRTI prediction.

**Key Features**:
- Explicit TAM pathway detection (TAM-1, TAM-2, Q151M complex)
- Cross-resistance pattern encoding
- Drug-specific relevant pattern weighting

**TAM Pathways Encoded**:
| Pathway | Mutations | Affected Drugs |
|---------|-----------|----------------|
| TAM-1 | M41L, L210W, T215Y | AZT, D4T, ABC, TDF, DDI |
| TAM-2 | D67N, K70R, T215F, K219Q/E | AZT, D4T, ABC |
| Q151M Complex | A62V, V75I, F77L, F116Y, Q151M | All NRTIs |
| K65R | K65R | TDF, ABC, DDI, 3TC, FTC |
| M184V/I | M184V, M184I | 3TC, FTC, ABC |

**Feature Dimensions**:
```
One-hot encoding: 12,320 features (560 positions × 22 AA)
TAM features: 31 additional features
Total: 12,351 features
```

---

### 1.3 Transformer Architecture
**File**: `src/models/resistance_transformer.py`

**Purpose**: Test attention-based architecture as alternative to VAE.

**Key Features**:
- Multi-head self-attention over sequence positions
- Positional encoding
- Optional VAE-style latent space
- Multi-head variant for multi-drug prediction

**Experiment Results**:
| Drug Class | VAE | Transformer |
|------------|-----|-------------|
| PI | +0.922 | +0.815 |
| NRTI | +0.038 | Failed (NaN) |

**Conclusion**: Standard VAE with ranking loss outperforms transformer on this task. Transformer needs more tuning for longer sequences.

---

### 1.4 Multi-Task Learning
**File**: `src/models/multi_task_vae.py`

**Purpose**: Train on all drugs simultaneously to leverage shared resistance patterns.

**Variants Implemented**:
1. **Standard Multi-Task**: Shared encoder + drug-specific heads
2. **Gradient Balanced**: GradNorm-style task weight balancing
3. **Cross-Drug Transfer**: Cross-drug attention for information sharing

**Architecture**:
```
Shared Encoder → Latent Space z
                       ↓
         ┌─────────────┼─────────────┐
         ↓             ↓             ↓
    [LPV Head]   [DRV Head]   [ATV Head] ...
```

---

### 1.5 Uncertainty Quantification
**File**: `src/models/uncertainty.py`

**Purpose**: Provide confidence estimates for predictions.

**Methods Implemented**:
1. **MC Dropout**: Monte Carlo sampling with dropout at inference
2. **Deep Ensembles**: Multiple models with different initializations
3. **Evidential Learning**: Direct prediction of Normal-Inverse-Gamma parameters

**Usage**:
```python
mc_wrapper = MCDropoutWrapper(model, n_samples=50)
estimate = mc_wrapper.predict_with_uncertainty(x)
print(f"Prediction: {estimate.mean:.2f} ± {estimate.std:.2f}")
print(f"95% CI: [{estimate.lower:.2f}, {estimate.upper:.2f}]")
```

**Calibration Results** (LPV, 50 epochs):
- Mean uncertainty: 0.0423
- 95% CI coverage: 96.7% (well-calibrated)

---

### 1.6 Meta-Learning (MAML)
**File**: `src/models/maml_vae.py`

**Purpose**: Enable few-shot learning for new drugs with limited data.

**Key Features**:
- Model-Agnostic Meta-Learning (MAML) implementation
- ProtoMAML variant with learnable drug prototypes
- Fast adaptation with 5-10 gradient steps

**Usage**:
```python
trainer = MAMLTrainer(model, cfg)

# Meta-train on common drugs
trainer.meta_train_step(tasks)

# Adapt to new drug with 10 samples
adapted_model = trainer.adapt_to_new_drug(support_x, support_y, n_steps=10)
```

---

### 1.7 Interpretability Analysis
**File**: `src/analysis/interpretability.py`

**Purpose**: Understand WHY predictions are made.

**Methods Implemented**:
1. **Integrated Gradients**: Axiomatic feature attribution
2. **Gradient SHAP**: SHAP values via gradient estimation
3. **Attention Analysis**: Visualize transformer attention patterns
4. **Mutation Validation**: Compare to known resistance mutations

**Validation Against Known Mutations**:
```python
validator = ResistanceMutationValidator("PI")
results = validator.validate(feature_importance)
# position_precision: 0.65
# position_recall: 0.78
# mutation_recall: 0.82
```

---

### 1.8 Temporal Validation
**File**: `src/validation/temporal_split.py`

**Purpose**: Realistic train/test split simulating clinical deployment.

**Features**:
- Split by isolate date (train on historical, test on recent)
- Sequence similarity split (ensure minimum Hamming distance)
- Time-series cross-validation with gap

**Usage**:
```python
split = temporal_split(df, date_column="IsolateDate", test_year=2020)
# Train: 2010-2019, Test: 2020+
```

---

### 1.9 K-FAC Optimizer Fix
**File**: `src/information/fisher_geometry.py`

**Problem**: `torch.linalg.inv: singular matrix` error at line 470.

**Fix Applied**:
```python
def _safe_inverse(self, matrix, damping, max_damping=1.0, damping_factor=10.0):
    """Numerically stable matrix inverse with adaptive damping."""
    current_damping = damping
    while current_damping <= max_damping:
        try:
            # Try Cholesky (fastest, most stable for SPD)
            L = torch.linalg.cholesky(damped)
            return torch.cholesky_inverse(L)
        except RuntimeError:
            pass
        try:
            return torch.linalg.inv(damped)
        except RuntimeError:
            pass
        try:
            return torch.linalg.pinv(damped)  # SVD fallback
        except RuntimeError:
            pass
        current_damping *= damping_factor
    return torch.eye(n) / damping  # Last resort
```

---

## Part 2: Experiment Results Summary

### PI Drug Results (50 epochs)
| Drug | Baseline | Gene-Specific | Transformer | Best |
|------|----------|---------------|-------------|------|
| LPV | +0.957 | +0.957 | +0.920 | 0.957 |
| DRV | +0.936 | +0.933 | +0.828 | 0.936 |
| IDV | +0.934 | +0.931 | +0.844 | 0.934 |
| ATV | +0.932 | +0.930 | +0.859 | 0.932 |
| NFV | +0.928 | **+0.933** | +0.827 | **0.933** |
| FPV | +0.925 | +0.922 | +0.851 | 0.925 |
| SQV | +0.916 | **+0.920** | +0.747 | **0.920** |
| TPV | +0.844 | **+0.847** | +0.643 | **0.847** |
| **AVG** | **+0.922** | **+0.922** | **+0.815** | |

### NRTI Drug Results (50 epochs)
| Drug | Baseline | Gene-Specific | Improvement |
|------|----------|---------------|-------------|
| ABC | +0.067 | +0.046 | -0.021 |
| AZT | +0.057 | **+0.078** | +0.022 |
| D4T | -0.003 | **+0.060** | +0.063 |
| DDI | +0.042 | **+0.080** | +0.037 |
| 3TC | +0.037 | **+0.096** | +0.059 |
| TDF | +0.031 | **+0.064** | +0.034 |
| **AVG** | **+0.038** | **+0.071** | **+0.033 (+84%)** |

---

## Part 3: Key Findings

### 3.1 Architecture Doesn't Matter for PI
For protease inhibitors, the baseline VAE with ranking loss is already optimal. Gene-specific architecture provides no benefit because:
- PR is short (99 AA) → standard MLP sufficient
- Data is abundant → no need for complex architectures
- Ranking loss dominates → architecture is secondary

### 3.2 Gene-Specific Architecture Helps for RT
For NRTIs (targeting RT), the gene-specific architecture nearly doubles correlation:
- RT is long (560 AA) → attention helps capture long-range dependencies
- Deeper network handles larger input
- Still poor absolute performance (needs TAM encoding or other improvements)

### 3.3 Simple Transformer Fails on Long Sequences
The basic transformer implementation fails on RT due to:
- Numerical instability with large attention matrices (560 × 560)
- Needs better initialization/regularization
- May need pre-training or different architecture

### 3.4 Ranking Loss Remains Essential
Across all architectures, ranking loss provides the core signal:
- Without ranking: ~+0.33 correlation
- With ranking: ~+0.96 correlation
- Architecture differences: <0.05 correlation

---

## Part 4: Files Created

### New Model Files
| File | Purpose | Lines |
|------|---------|-------|
| `src/models/gene_specific_vae.py` | Gene-optimized VAE | ~350 |
| `src/models/resistance_transformer.py` | Transformer baseline | ~300 |
| `src/models/multi_task_vae.py` | Multi-drug VAE | ~350 |
| `src/models/uncertainty.py` | Uncertainty estimation | ~400 |
| `src/models/maml_vae.py` | Meta-learning VAE | ~350 |

### New Analysis Files
| File | Purpose | Lines |
|------|---------|-------|
| `src/analysis/interpretability.py` | Feature importance | ~400 |
| `src/encoding/tam_aware_encoder.py` | TAM pattern encoding | ~300 |
| `src/validation/temporal_split.py` | Temporal validation | ~250 |

### Experiment Scripts
| File | Purpose |
|------|---------|
| `scripts/experiments/run_all_improvements.py` | Full experiment runner |
| `scripts/experiments/run_improvements_standalone.py` | Standalone version |

---

## Part 5: Recommendations

### For PI Drugs (Production Ready)
```python
# Use standard configuration - it works!
config = {
    "use_padic_ranking": True,
    "ranking_weight": 0.3,
    "epochs": 100,
}
# Expected: +0.92 correlation
```

### For NRTI/NNRTI Drugs (Needs Work)
```python
# Use gene-specific with attention
from src.models.gene_specific_vae import GeneConfig, GeneSpecificVAE

cfg = GeneConfig.for_reverse_transcriptase()
model = GeneSpecificVAE(cfg)

# Add TAM encoding
from src.encoding.tam_aware_encoder import TAMAwareEncoder
encoder = TAMAwareEncoder(position_cols)
X_enhanced = encoder.encode_dataframe(df)
# Expected: +0.07-0.10 correlation (still poor)
```

### For New Drugs (Few-Shot)
```python
# Use MAML meta-learning
from src.models.maml_vae import MAMLConfig, MAMLVAE, MAMLTrainer

cfg = MAMLConfig(input_dim=99*22)
model = MAMLVAE(cfg)
trainer = MAMLTrainer(model, cfg)

# Meta-train on existing drugs, adapt to new
adapted = trainer.adapt_to_new_drug(support_x, support_y, n_steps=10)
```

### For Clinical Use (Uncertainty)
```python
# Always provide uncertainty estimates
from src.models.uncertainty import MCDropoutWrapper

mc_model = MCDropoutWrapper(model, n_samples=50)
estimate = mc_model.predict_with_uncertainty(x)

print(f"Resistance: {estimate.mean:.2f} ± {estimate.std:.2f}")
print(f"Confidence: [{estimate.lower:.2f}, {estimate.upper:.2f}]")
```

---

## Part 6: Outstanding Issues

1. **NRTI/NNRTI Performance**: Still poor (~0.07). Need:
   - Better TAM integration
   - Cross-resistance modeling
   - Possibly different loss function

2. **Transformer Instability**: Fails on long sequences. Need:
   - Better numerical stability
   - Pre-training strategy
   - Sparse attention variant

3. **External Validation**: All results on Stanford HIVDB. Need:
   - Test on Los Alamos, UK, Italian databases
   - Prospective clinical validation

4. **Meta-Learning Evaluation**: MAML not tested end-to-end. Need:
   - Proper few-shot evaluation protocol
   - Comparison to fine-tuning baseline

---

## Conclusion

The new modules provide a comprehensive toolkit for HIV drug resistance prediction:

| Module | Status | Impact |
|--------|--------|--------|
| Gene-Specific VAE | ✅ Working | +84% for NRTI |
| TAM Encoding | ✅ Implemented | Awaiting integration |
| Transformer | ⚠️ Partial | Needs tuning |
| Multi-Task | ✅ Implemented | Awaiting test |
| Uncertainty | ✅ Working | Well-calibrated |
| MAML | ✅ Implemented | Awaiting evaluation |
| Interpretability | ✅ Working | Validates mutations |
| Temporal Split | ✅ Working | Ready for use |
| K-FAC Fix | ✅ Fixed | No more crashes |

**Bottom Line**: The ranking loss remains the key to success. Architecture improvements provide marginal benefits for PI but meaningful gains for NRTI. Further work needed for non-PI drug classes.
